[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaginitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaginitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,96,120,142,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639817","large-algorithm-setting-and-validation-study-100639817",false,"NCT07607470","Large Algorithm Setting and Validation Study","A Non-Significant Risk Specimen Collection Study to Obtain Vaginal Swab Samples for Algorithm Development and Testing","LAVA","Inclusion Criteria:\n\nBiologically female participants, ≥ 18 years of age, with at least one of the following symptoms of vaginitis:\n\n* Abnormal vaginal discharge\n* Vaginal or vulvar itching, burning, or irritation\n* Painful or uncomfortable intercourse\n* Vaginal odor\n* Painful or frequent urination\n\nExclusion Criteria:\n\n* Participants who do not meet the above-described inclusion criteria will be excluded from the study.\n* Previously enrolled in this study\n* Contraindication to vaginal swab sampling","FEMALE","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","In this pilot study, prospectively acquired clinician-collected and participant-collected vaginal swab specimens will be obtained from up to 1000 individuals with signs and symptoms of vaginitis to develop and validate a bacterial vaginosis diagnostic algorithm and evaluate the performance of the Nanopath assay.\n\nThe Nanopath assay is an amplification-free molecular test that detects pathogens associated with vaginitis. The performance of the Nanopath assay will be assessed by comparing Nanopath assay results to previously FDA-cleared commercial tests and yeast culture.",[25,26,27,28,29,30,31,32,33,34,35,36,37],"Bacterial Infections","Bacterial Infections and Mycoses","Infections","Vaginitis","Vaginal Diseases","Genital Diseases, Female","Female Urogenital Diseases","Urogenital Disease","Candidiasis","Mycoses","Vulvovaginitis","Vulvar Diseases","Vaginosis, Bacterial","NOT_YET_RECRUITING","2026-05-20",{"date":41,"type":42},"2026-05-26","ACTUAL",{"date":39,"type":21},{"date":45,"type":21},"2027-01",{"name":47,"class":48},"Nanopath, Inc","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":73,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":49},"100633458","phase-4-vaginal-estradiol-vs-moisturizer-to-improve-postmenopausal-vaginal-aging-symptoms-and-the-microbiome-in-women-living-with-hiv-100633458","NCT07526948","Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV","Vaginal Estradiol Versus Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms, Dysbiosis and Markers of Latency Reversal in Menopausal Women Living With HIV","Inclusion Criteria:\n\n* female\n* at least 40 years old\n* menopausal (no menses in 12 months) within 2 years of last menstrual period or perimenopausal in the late menopausal transition, defined as an interval of amenorrhea greater than or equal to 60 days\n* have symptoms of the genitourinary syndrome of menopause (GSM) which developed within the prior 2 years. Symptoms of GSM include vaginal symptoms including dryness, soreness, itching, irritation and dyspareunia and\u002For urinary symptoms including urgency, frequency and recurrent urinary tract infections (UTIs)\n\nExclusion Criteria:\n\n* Unexplained or unevaluated abnormal genital bleeding\n* Current or suspected pregnancy\n* Desired pregnancy\n* If less than 55 years old, have had a hysterectomy and have at least one ovary (as menopause cannot be determined in this case by amenorrhea alone)\n* Pelvic or vaginal surgery in the prior 60 days\n* Used systemic reproductive hormones in the last 2 months\n* Used antibiotics in the last 30 days\n* Used immunosuppressive medications in the prior 60 days including biologics, chemotherapeutics or post transplant immunosuppressive medications\n* Used any vaginal or vulvar preparations in the last month\n* Current active vaginal infection diagnosed at study entry\n* Any serious disease or condition that may interfere with study compliance\n* Current or previous history of breast cancer or estrogen dependent cancer (e.g., ovarian, endometrial)\n* Current or previous history of deep vein thrombosis or pulmonary embolism\n* Current or previous history of myocardial infarction or stroke\n* Known clotting disorder including Protein C, Protein S and antithrombin deficiency, Factor V Leiden or prothrombin mutations\n* Known severe liver disease including cirrhosis or active Hepatitis B\n* Known allergic reaction to Vagifem (estradiol vaginal tablet) or Replens",true,"40 Years","70 Years",{"count":61,"type":21},62,"INTERVENTIONAL",[64],"PHASE4","This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.",[67,68,69,70,71,28,72],"Menopausal Complaints","Vaginal Atrophy","Genitourinary Symptoms","HIV (Human Immunodeficiency Virus)","Menopause Related Conditions","Perimenopause",[74,75,76,77,78,79,80,81,82,83,84,85],"Pain with sex","Vaginal dryness","Symptoms of menopause","HIV Infection","Menopause","Vaginal microbiome","Dysbiosis","Aging","Premature aging","Atrophic vaginitis","Genitourinary syndrome of menopause (GSM)","Symptoms of perimenopause","2026-04-08",{"date":88,"type":42},"2026-04-14",{"date":90,"type":21},"2026-06-01",{"date":92,"type":21},"2031-06-30",{"name":94,"class":95},"Albert Einstein College of Medicine","OTHER",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":62,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100630821","phase-4-clinical-study-on-the-prevention-and-treatment-of-radiation-vaginitis-with-triethanolamine-cream-100630821","NCT07492654","Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream","Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream: An Open-label, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n1. Age 18-75 years old;\n2. Those diagnosed with cervical cancer by histological pathology and receiving radiotherapy with a total radiation dose of ≥70Gy;\n3. ECOG score: 0-2 levels;\n4. Normal mental state and clear consciousness;\n5. Be able to cooperate with the visitor;\n6. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Those with severe immune deficiency (such as those who have recently received bone marrow transplantation, with long-term high-dose glucocorticoids \\> 20 mg\u002F day for more than 2 weeks);\n2. Congenital vaginal malformations;\n3. Patients who are pregnant, breastfeeding, or have plans and the possibility of becoming pregnant;\n4. Other conditions that the researcher deems unsuitable for enrollment (such as: previous allergy history to triethanolamine cream, etc.).","75 Years",{"count":105,"type":21},238,[64],"The objective of this clinical trial is to understand whether triethanolamine cream can prevent and treat acute radiation vaginitis. It will also learn about the safety of triethanolamine cream. The main questions it aims to answer include:\n\nCan triethanolamine cream reduce the incidence and severity of radiation vaginitis in cervical cancer patients undergoing radiotherapy?\n\nWhat medical problems might participants encounter when using triethanolamine cream?\n\nResearchers will compare triethanolamine cream with routine care to observe whether triethanolamine cream will reduce the incidence and severity of radiation vaginitis in cervical cancer patients receiving radiotherapy.\n\nParticipants will:\n\nDaily vaginal administration of triethanolamine cream, vaginal opening application and routine care, or only routine care, from the first day of radiotherapy until 28 days after the end of radiotherapy.\n\nFour examinations were conducted respectively from before radiotherapy to 90 days after its end.\n\nRecord their symptoms and conduct injury scoring.",[28,109],"Radiotherapy Induced Mucositis","2026-03-19",{"date":112,"type":42},"2026-03-25",{"date":114,"type":21},"2026-03-01",{"date":116,"type":21},"2030-12-31",{"name":118,"class":119},"Fujian Cancer Hospital","OTHER_GOV",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":62,"phases":128,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":49},"100521504","prospective-evaluation-of-infectious-vulvovaginitis-on-wound-complication-rates-after-vulvar-excision-for-premalignant-lesions-100521504","NCT06070454","Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions","Inclusion Criteria:\n\n* Must be 18 years of age\n* Has histologically confirmed non-malignant vulvar pathology\n* Is scheduled or planning for WLE\u002FSPV\n* Signed informed consent obtained prior to any protocol specific procedures\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Women who are pregnant or nursing (lactating) women at time of consent\n* No prior RT\n* No recent antibiotic use within the last 3 weeks or 5.5 times the half-life of the antibiotic (whichever is shorter)\n* No history of prior malignancy within the last 3 years that required systemic chemotherapy or radiation\n* Not immunosuppressed or compromised\n* No active HIV (must have undetectable viral load)\n* Chronic treatment with corticosteroids or other immunosuppressive agents including topical corticosteroids in the pelvis. Inhaled corticosteroids are allowed\n* No active uncontrolled severe infections (not responding to antibiotics), except acute or chronic pelvic inflammatory disease\n* Uncontrolled diabetes mellitus",{"count":127,"type":21},91,[129],"NA","Primary:\n\n* To measure the rate of perioperative vulvovaginitis in a population of patients in central VA with non-malignant vulvar disease who require surgical excision\n* To correlate the rate of vulvovaginitis with rate of wound cellulitis and incisional breakdown in patients undergoing SPV\u002FWLE for vulvar disease We will use a vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida. The swab will be collected preoperatively on day of surgery. The outcome will be evaluated by phone call to patient at 1 week after surgery and physical exam at the postoperative visit between 4-6 weeks.",[28,36],"RECRUITING","2025-10-16",{"date":135,"type":42},"2025-10-20",{"date":137,"type":42},"2024-04-25",{"date":139,"type":21},"2026-08-01",{"name":141,"class":95},"University of Virginia",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":62,"phases":152,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":49},"100406566","phase-3-treatment-for-aerobic-vaginitis-by-using-bofukang-vaginal-suppository-100406566","NCT04574089","Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository","Medical Ethics Committee of Peking University Shenzhen Hospital","Inclusion Criteria:\n\nAerobic vaginitis diagnosed based on present ：\n\n1. Vaginal dischareg ;\n2. pH \\> 4.5;\n3. Donders score≥3;\n\nExclusion Criteria:\n\n1. Patients with other vaginitis, cervical erosion, or suspected gonorrhea, herpes simplex virus infection and other vulvar diseases;\n2. Patients received systemic or vaginal antifungal or antibiotic treatment within two weeks before admission.\n3. Pregnancy, lactation and intentional pregnancy;\n4. Women with liver and kidney dysfunction, low immune function, diabetes, psychosis or other serious diseases;\n5. Allergic constitution and patients allergic to drug ingredients in this study;\n6. Those with poor compliance.","55 Years",{"count":151,"type":21},50,[153],"PHASE3","Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang Suppository 14 days group.To evaluate the efficacy and safety after treatment.",[28],[157,158],"Aerobic vaginitis","Treatment","2025-06-09",{"date":161,"type":42},"2025-06-12",{"date":163,"type":42},"2020-05-01",{"date":165,"type":21},"2026-12-30",{"name":167,"class":95},"Peking University Shenzhen Hospital",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":62,"phases":178,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100575344","phase-2-a-study-of-the-efficacy-and-safety-of-wxsh0102-in-treating-vcc-patients-100575344","NCT06771063","A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients","A Multicenter, Randomized, Double-blind, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of WXSH0102 Tablets in the Treatment of Vulvovaginal Candidiasis (VVC)","Inclusion Criteria:\n\n* The subjects understood and voluntarily signed the informed consent Form (ICF), and were willing and able to comply with the study protocol.\n* Female participants who signed ICF at the age of 18-64 years (including the cut-off value) and had sexual intercourse;\n* Participants were diagnosed with VVC and met each of the following criteria: a. At screening, the total score on the VVC scale was ≥4 and at least two of the symptoms or signs on the VVC scale were present; b. A vaginal discharge sample collected at screening was Gram stain positive for Candida (hypha\u002Fpseudohypha\u002Fbudding); c. Vaginal pH ≤4.5; Symptoms: vulvovaginal itching, vulvar burning pain, dyspareunia and urination pain, excessive secretion, secretion is tofu residue like; Physical signs: gynecological examination showed vulvar hyperemia and edema, which may be accompanied by scratches. In severe cases, chapped skin, exfoliation and even erosion could be seen. Vaginal mucosa was hyperemic, vaginal secretion was curd or tofu residue like;\n* Subjects who are capable of oral administration;\n* For the duration of the study, participants agreed to abstain from sexual activity and to use the condom throughout sexual activity.\n\nExclusion Criteria:\n\n* Known or suspected allergic history to any component of this product, fluconazole or pyrrole drugs;\n* Subjects with any vulvovaginal or cervical disease that may affect the diagnosis and evaluation of VVC;\n* Topical or systemic antifungal treatment for VVC within 14 days before randomization;\n* Significant liver disease or abnormal liver function tests (alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\] \\> 1.5 ULN); Patients with severe renal disease or renal insufficiency (glomerular filtration rate (GFR) \\\u003C 60ml\u002Fmin\u002F1.73m2 );\n* Patients who planned to undergo treatment or surgery for vulvar, vaginal or cervical lesions during the study period;\n* Severe gastrointestinal disease or other conditions that may affect the absorption of the trial drug;\n* Patients with severe heart, lung, liver, kidney dysfunction and hematopoietic system diseases;","64 Years",{"count":177,"type":21},108,[179],"PHASE2","This study is a multicenter, randomized, double-blind, active-controlled, dose-ranging clinical trial designed to evaluate the efficacy and safety of the investigational drug compared to the active comparator in the treatment of vulvovaginal candidiasis. The trial consists of three phases: screening\u002Fenrollment (D-3 to D-1), treatment period (D1 to D3), and follow-up period (D4, D11±2, D25±3). Eligible subjects in this study will be randomized in a 1:1:1:1 ratio to three investigational drug arms with different dosing regimens and one active control arm. Specifically, Group A will receive WXSH0102 tablets with 1400 mg on the first day followed by a maintenance dose of 700 mg for two consecutive days, Group B will receive WXSH0102 tablets with 1000 mg on the first day followed by a maintenance dose of 500 mg for two consecutive days, Group C will receive WXSH0102 tablets with 600 mg on the first day followed by a maintenance dose of 300 mg for two consecutive days, and Group D (active control group) will receive fluconazole capsules for only one day on D1. All medications will be administered orally.",[28],"2025-02-11",{"date":184,"type":42},"2025-02-13",{"date":186,"type":42},"2025-01-13",{"date":188,"type":21},"2025-07-31",{"name":190,"class":48},"Cisen Pharmaceutical CO., LTD.",2]